title: Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer: phase II study.
abstract: A phase II study was conducted to evaluate the safety and efficacy of the combination GIP (gemcitabine, ifosfamide, and cisplatin) for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Thirty patients with stage III B/IV NSCLC were treated with a combination of GIP. Patients received gemcitabine 1,000 mg/m2 administered intravenously on days 1 and 8, ifosfamide 3,500 mg/m2 on day 2, and cisplatin 80 mg/m2 on day 2, repeated every 21 days. Two of the 30 patients (7%) showed a complete response and 14 patients (46%) showed a partial response. The overall response rate was 53%. The estimated median survival for all patients was 60 weeks. All patients enrolled onto the study were eligible for toxicity assessment. Toxicities were treatable and included World Health Organization grade III or IV leukopenia (29%), thrombocytopenia (18%), anemia (7%) and nausea, and vomiting (6%). Febrile neutropenia occurred in 3 of 30 patients. There were no treatment-related deaths. The combination therapy of GIP is active, well tolerated, and easy to administer on an outpatient basis in advanced NSCLC.
authors.affiliation: Division of Oncology, Hospital Ciudad de Jaen, Jaen, Spain.
authors.forename: Nicolás
authors.initials: N
authors.lastname: Mohedano Mohedano
authors.forename: Pedro
authors.initials: P
authors.lastname: Sánchez Rovira
authors.forename: Ana
authors.initials: A
authors.lastname: Lozano Barriuso
authors.forename: Margarita
authors.initials: M
authors.lastname: Fernandez Morales
authors.forename: Begoña
authors.initials: B
authors.lastname: Medina Magan
authors.forename: Ana
authors.initials: A
authors.lastname: Jaen Morago
authors.forename: Ignacio
authors.initials: I
authors.lastname: Porras Quintela
authors.forename: Rosario
authors.initials: R
authors.lastname: Dueñas Garcia
authors.forename: Encarna
authors.initials: E
authors.lastname: Fernandez Flores
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Moreno Moreno
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D007069:Ifosfamide; D000093542:Gemcitabine